Perioperative management of the paediatric patient with coexisting neuromuscular disease

British Journal of Anaesthesia

Volumn 107, Issue SUPPL. 1, 2011, Pages

  Lerman, J ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

age; cerebral palsy; child; dantrolene; malignant hyperthermia; mitochondrial myopathies; muscular dystrophies; preschool

Indexed keywords

DANTROLENE; DYSTROPHIN; HALOTHANE; LIDOCAINE; MIDAZOLAM; PROPOFOL; ROCURONIUM; SUXAMETHONIUM;

AUTOSOMAL DOMINANT DISORDER; BECKER MUSCULAR DYSTROPHY; CEREBRAL PALSY; DISEASE CLASSIFICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DUCHENNE MUSCULAR DYSTROPHY; EMERY DREIFUSS MUSCULAR DYSTROPHY; HEART DISEASE; HUMAN; INHALATION ANESTHESIA; INTRAVENOUS ANESTHESIA; MALIGNANT HYPERTHERMIA; MUSCLE INJURY; MUSCLE WEAKNESS; NEUROMUSCULAR DISEASE; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; REVIEW; X CHROMOSOME LINKED DISORDER;

EID: 83455233781     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aer335     Document Type: Review

References (84)

1. Baraka AN, Jalbout MI. Anesthesia and myopathy. Curr Opin Anaesthesiol 2002; 15: 371-6 (Pubitemid 34596919)
2. Britt BA, Endrenyi L, Frodis W, Scott E, Kalow W. Comparison of effects of several inhalation anaesthetics on caffeine-induced contractures of normal and malignant hyperthermic skeletal muscle. Can Anaesth Soc J 1980; 27: 12-5 (Pubitemid 10141757)
3. Hopkins PM. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth 2011; 107: 48-56
4. Baur CP, Klingler W, Jurkat-Rott K, et al. Xenon does not induce contracture in human malignant hyperthermia muscle. Br J Anaesth 2000; 85: 712-6
5. Benca J, Hogan K. Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options. Anesth Analg 2009; 109: 1049-53
6. Klingler W, Rueffert H, Lehmann-Horn F, Girard T, Hopkins PM. Core myopathies and risk of malignant hyperthermia. Anesth Analg 2009; 109: 1167-73
7. Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. J Am Med Assoc 2005; 293: 2918-24 (Pubitemid 41029146)
8. Brandom BW. Genetics of malignant hyperthermia. Sci World J 2006; 6: 1722-30 (Pubitemid 46045421)
9. Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006; a report from the North American Malignant Hyperthermia registry of the Malignant Hyperthermia Association of the United States. Anesthesiology 2008; 108: 603-11 (Pubitemid 351440580)
10. Litman RS, Flood CD, Kaplan RF, Kim YL, Tobin JR. Postoperative malignant hyperthermia; an analysis of cases from the North American Malignant Hyperthermia registry. Anesthesiology 2008; 109: 825-9
11. Lazzell VA, Carr AS, Lerman J, Burrows FA, Creighton RE. The incidence of masseter muscle rigidity after succinylcholine in infants and children. Can J Anaesth 1994; 41: 475-9 (Pubitemid 24230420)
12. Petroz GC, Lerman J. Preparation of the Siemens KION anesthetic machine for patients susceptible to malignant hyperthermia. Anesthesiology 2002; 96: 941-6 (Pubitemid 34266689)
13. Kim TW, Nemergut ME. Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice. Anesthesiology 2011; 114: 205-12
14. Sabouri AS, Lerman J, Heard C. Residual sevoflurane may be present after flushing the BE anesthesia workstation for MH susceptible patients. Anesthesiology 2011; 115: A1276
15. Birgenheier N, Stoker R, Westenskow D, Orr J. Activated charcoal effectively removes inhaled anesthetics from modern anesthesia machines. Anesth Analg 2011; 112: 1363-70
16. Crawford MW, Prinzhausen H, Petroz GC. Accelerating the washout of inhalational anesthetics from the Drager Primus anesthetic workstation: effect of exchangeable internal components. Anesthesiology 2007; 106: 289-94 (Pubitemid 46185174)
17. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110: 498-507
18. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-9 (Pubitemid 24128939)
19. Capacchione JF, McGuire DP, Long RP, Michalowicz M, Muldoon S. Is the malignant hyperthermia (MH) clinical grading scale an accurate predictor of MH susceptibility? Anesthesiology 2011; 115: A1521
20. Inan S, Wei H. The cytoprotective effects of dantrolene: a ryanodine receptor antagonist. Anesth Analg 2010; 111: 1400-10
21. Mitchell LW, Leighton BL. Warmed diluent speeds dantrolene reconstitution. Can J Anaesth 2003; 50: 127-30 (Pubitemid 36395140)
22. Gerbershagen MU, Becker S, Starosse A, Wappler F. Comparison of therapeutic effectiveness of dantrolene and ryanodex in porcine malignant hyperthermia. Anesthesiology 2007; 107: A1922
23. Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia - A multicenter study. Anesthesiology 1982; 56: 254-62
24. Brandom BW, Larach MG, Chen MS, Young MC. Complications associated with the administration of dantrolene 1987-2006: a report from the North American Malignant Hyperthermia registry of the Malignant Hyperthermia association of the United States. Anesth Analg 2011; 112: 1115-23
25. Lerman J, McLeod ME, Strong HA. Pharmacokinetics of intravenous dantrolene in children. Anesthesiology 1989; 70: 625-9 (Pubitemid 19097384)
26. Burkman JM, Posner KL, Domino KB. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology 2007; 106: 901-6 (Pubitemid 46684055)
27. Blake DJ, Kroger S. The neurobiology of Duchenne muscular dystrophy: learning lessons from muscle? Trends Neurosci 2000; 23: 92-99
28. Gurnaney H, Brown A, Litman RS. Malignant hyperthermia and muscular dystrophies. Anesth Analg 2009; 109: 1043-8
29. Yemen TA, McClain C. Muscular dystrophy, anesthesia and the safety of inhalational agents revisited; again. Paediatr Anaesth 2006; 26: 105-8
30. Whitehead NP, Yeung EW, Allen DG. Muscle damage in MDX (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 2006; 33: 657-62 (Pubitemid 43894030)
31. Allen DG, Whitehead NP. Duchenne muscular dystrophy-what causes the increased membrane permeability in skeletal muscle? Int J Biochem Cell Bio 2011; 43: 290-4
32. Goodwin FC, Muntoni F. Cardiac involvement in muscular dystrophies: molecular mechanisms. Muscle Nerve 2005; 32: 577-88 (Pubitemid 41504843)
33. Hsu DT. Cardiac manifestations of neuromuscular disorders in children. Paediatr Respir Rev 2010; 11: 35-8
34. Verma S, Anziska Y, Cracco J. Review of Duchenne muscular dystrophy (DMD) for the pediatricians in the community. Clin Pediatr 2010; 49: 1011-17
35. Allen J. Pulmonary complications of neuromuscular disease: a respiratory mechanics perspective. Paediatr Respir Rev 2010; 11: 18-23
36. Arens R, Muzumdar H. Sleep, sleep disordered breathing, and nocturnal hypoventilation in children with neuromuscular diseases. Paediatr Respir Rev 2010; 11: 24-30
37. Lerman J. A disquisition on sleep-disordered breathing in children. Paediatr Anaesth 2009; 19(Suppl. 1): 100-8
38. Finsterer J, Ramaciotti C, Wang CH, et al. Cardiac findings in congenital muscular dystrophies. Pediatrics 2010; 126: 538-45
39. Wick S, Muenster T, Schmidt J, Forst J, Schmitt HJ. Onset and duration of rocuronium-induced neuromuscular blockade in patients with Duchenne muscular dystrophy. Anesthesiology 2005; 102: 915-9 (Pubitemid 40586531)
40. Turturro F, Rocca B, Gumina S, et al. Impaired primary hemostasis with normal platelet function in Duchenne muscular dystrophy during highly-invasive spinal surgery. Neuromuscl Disord 2005; 15: 532-40 (Pubitemid 41033007)
41. Driessen JJ. Neuromuscular and mitochondrial disorders: what is relevant to the anaesthesiologist? Curr Opin Anaesthesiol 2008; 21: 350-5
42. Driessen J, Willems S, Dercksen S, Giele J, Van der Staak F, Smeitink J. Anesthesia-related morbidity and mortality after surgery for muscle biopsy in children with mitochondrial defects. Paediatr Anaesth 2007; 17: 16-21 (Pubitemid 44924372)
43. Shipton EA, Prosser DO. Mitochondrial myopathies and anaesthesia. Eur J Anaesthesiol 2004; 21: 173-8 (Pubitemid 38297912)
44. Skladal D, Halliday J, Thorburn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003; 126: 1905-12 (Pubitemid 36917349)
45. Schapira AHV. Mitochondrial myopathies; mechanisms now better understood. Br Med J 1989; 298: 1127-8 (Pubitemid 19121345)
46. Christodoulou J. Genetic defects causing mitochondrial respiratory chain disorders and disease. Hum Reprod 2000; 15 (Suppl 2): 28-43
47. Rahman S, Hanna MG. Diagnosis and therapy in neuromuscular disorders: diagnosis and new treatments in mitochondrial disease. J Neurol Neurosurg Psychiatry 2009; 80: 943-53
48. Mancuso M, Orsucci D, Coppede F, Nesti C, Choub A, Siciliano G. Diagnostic approach to mitochondrial disorders: the need for a reliable biomarker. Curr Mol Med 2009; 9: 1095-107
49. Darin N, Oldfors A, Moslemi AR, Holme E, Tulinius M. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities. Ann Neurol 2001; 49: 377-83 (Pubitemid 32202792)
50. Muravchick S. Clinical implications of mitochondrial disease. Adv Drug Deliv Rev 2008; 60: 1553-60
51. Di Donato S. Multisystem manifestations of mitochondrial disorders. J Neurol 2009; 256: 693-710
52. Holmgren D, Wahlander H, Eriksson BO, Oldfors A, Holme E, Tulinius M. Cardiomyopathy in children with mitochondrial disease: clinical course and cardiological findings. Eur Heart J 2003; 24: 280-8 (Pubitemid 36207084)
53. Hassani A, Horvath R, Chinnery PF. Mitochondrial myopathies: developments in treatment. Curr Opin Neurol 2010; 23: 459-65
54. Muravchick S, Levy RJ. Clinical implications of mitochondrial dysfunction. Anesthesiology 2006; 105: 819-37 (Pubitemid 44477329)
55. Finsterer J, Segall L. Drugs interfering with mitochondrial disorders. Drug Chem Toxicol 2010; 33: 138-51
56. Wolf A, Weir P, Segar P, Stone J, Shield J. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001; 357: 606-7 (Pubitemid 32179617)
57. Short TG, Young Y. Toxicity of intravenous anaesthetics. Best Pract Res Clin Anaesthesiol 2003; 17: 77-89 (Pubitemid 38950014)
58. Vilela H, Garcia-Fernandez J, Parodi E, Reinosos-Barbero F, Duran P, Gilsanz F. Anesthetic management of a patient with MERRF syndrome. Paediatr Anaesth 2005; 15: 77-9 (Pubitemid 40188799)
59. Aouad MT, Gerges FJ, Baraka AS. Resistance to cisatracurium in a patient with MELAS syndrome. Paediatr Anaesth 2005; 15: 1124-7 (Pubitemid 43965395)
60. Footitt EJ, Sinha MD, Raiman JA, Dhawan A, Moganasundram S, Champion MP. Mitochondrial disorders and general anaesthesia: a case series and review. Br J Anaesth 2008; 100: 436-41 (Pubitemid 351773607)
61. Dodge NN. Cerebral palsy: medical aspects. Pediatr Clin North Am 2008; 55: 1189-207
62. Paneth N. Establishing the diagnosis of cerebral palsy. Clin Obstet Gynecol 2008; 51: 742-8
63. Paneth N, Hong T, Korzeniewski S. The descriptive epidemiology of cerebral palsy. Clin Perinatol 2006; 33: 251-67 (Pubitemid 43831170)
64. Nelson KB. Causative factors in cerebral palsy. Clin Obstet Gynecol 2008; 51: 749-62
65. Nolan J, Chalkiadis GA, LowJ,Olesch CA, Brown TC. Anaesthesia and pain management in cerebral palsy. Anaesthesia 2000; 55: 32-41 (Pubitemid 30040029)
66. Goldfinger MM, Tripi PA. Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine. Paediatr Anaesth 2007; 17: 270-2 (Pubitemid 46181390)
67. Theroux MC, Akins RE. Surgery and anesthesia for children who have cerebral palsy. Anesth Clin North Am 2005; 23: 733-43 (Pubitemid 41681663)
68. Picard P, Tramer MR. Prevention of pain on injection with propofol: a quantitative systematic review. Anesth Analg 2000; 90: 963-9 (Pubitemid 30190810)
69. Jalota L, Kalira V, George E, et al. Prevention of pain on injection of propofol: systematic review and meta-analysis. Br Med J 2011; 342: d1110
70. Lerman J, Houle TT, Matthews BT, Houck J, Burrows FA. Propofol for tracheal intubation in children anesthetized with sevoflurane: a dose-response study. Paediatr Anaesth 2009; 19: 218-24
71. Dierdorf SF, McNiece WL, Rao CC, et al. Effect of succinylcholine on plasma potassium in children with cerebral palsy. Anesthesiology 1985; 62: 88-90 (Pubitemid 15163909)
72. Theroux MC, Akins RE, Barone C, Boyce B, Miller F, Dabney KW. Neuromuscular junctions in cerebral palsy. Presence of extrajunctional acetylcholine receptors. Anesthesiology 2002; 96: 330-5
73. Moorthy SS, Krishna G, Dierdorf SF. Resistance to vecuronium in patients with cerebral palsy. Anesth Analg 1991; 73: 275-7
74. Frei FJ, Haemmerle MH, Brunner R, Kern C. Minimum alveolar concentration for halothane in children with cerebral palsy and severe mental retardation. Anaesthesia 1997; 52: 1056-60 (Pubitemid 27487466)
75. Choudhry DK, Brenn R. Bispectral index monitoring: a comparison between normal children and children with quadriplegic cerebral palsy. Anesth Analg 2002; 95: 1582-5 (Pubitemid 35423943)
76. Ghai B, Makkar JK, Wig J. Postoperative pain assessment in preverbal children and children with cognitive impairment. Paediatr Anaesth 2008; 18: 462-77 (Pubitemid 351600174)
77. Fitzgerald DA, Follett J, Van Asperen PP. Assessing and managing lung disease and sleep disordered breathing in children with cerebral palsy. Paediatr Respir Rev 2009; 10: 18-24
78. Monitto CL, Greenberg RS, Kost-Byerly S, et al. The safety and efficacy of parent-/nurse-controlled analgesia in patients less than six years of age. Anesth Analg 2000; 91: 573-9
79. Muthusamy K, Recktenwall SM, Friesen RM, et al. Effectiveness of an anesthetic continuous-infusion device in children with cerebral palsy undergoing orthopaedic surgery. J Pediatr Orthop 2010; 30: 840-5
80. Wu YW, Croen LA, Shah SJ, Newman TB, Najjar DV. Cerebral palsy in a term population: risk factors and neuroimaging findings. Pediatrics 2006; 118: 690-7 (Pubitemid 46085426)
81. Grether JK, Nelson KB. Maternal infection and cerebral palsy in infants of normal birth weight. J Am Med Assoc 1997; 278: 207-11 (Pubitemid 27339585)
82. Nelson KB, Grether JK. Potentially asphyxiating conditions and spastic cerebral palsy in infants of normal birth weight. Am J Obstet Gynecol 1998; 179: 507-13 (Pubitemid 28413392)
83. Grether JK, Nelson KB, Cummins SK. Twinning and cerebral palsy: experience in four northern California counties, births 1983 through 1985. Pediatrics 1993; 92: 854-85
84. Pettersen B, Nelson KB, Watson L, Stanley F. Twins, triplets and cerebral palsy in births in Western Australia in the 1980s. Br Med J 1993; 307: 1239-43 (Pubitemid 23330504)